Stanford researchers have developed a method to activate, cryopreserve, and thaw T regulatory (Tregs) cells that preserves their viability, phenotype and function.
Stanford researchers have derived human multipotent germline stem cells (hMGSCs) from a testis biopsy. The biopsied cells show multiple characteristics of pluripotency.
Researchers in Dr. Mark Davis' lab have developed a patented method to perform multi-parametric phenotypic analysis and T cell receptor (TCR) sequencing from single sorted T cells.
An interdisciplinary team of Stanford researchers have developed MagSweeper, a patented robotic liquid biopsy device that efficiently isolates and purifies live CTCs (circulating tumor cells) from blood while removing 100% of contaminating blood cells.
Researchers at Stanford have created a method to differentiate human pluripotent stem cells (hPSCs) into >90% pure hematopoietic stem cell (HSC)-like cells, which serve as progenitors to blood and immune cells.
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an efficacious therapy for patients with life-threatening leukemias, but its use has been hindered by the limited availability of donors with matching HLA. Graft manipulation by removing ??
A team of Stanford researchers has developed a novel method for quickly and efficiently generating human induced pluripotent stem cells (hiPSCs) using human adipose stem cells (hASCs) as the starting population.
Researchers in Dr. Dean Felsher's lab have generated a murine hepatocellular carcinoma (HCC) cell line with controllable MYC expression. HCC is one of the most common and incurable malignancies.
293T is a human cell line that has unique properties useful in many applications, including those requiring efficient transfection, gene expression, DNA replication, or viral production.
Engineers in Prof. Shan Wang's laboratory have developed a patented magnetic sifter device for high throughput cell sorting. This technology employs magnetic nanobead probes to tag cells of interest from raw samples.
Researchers at Stanford have developed a method to direct T cell fate toward the T stem cell memory (TSCM) phenotype during ex vivo expansion for adoptive cell transfer (ACT) therapies.
Obtaining pure cell types from mixed cell populations continues to be a significant obstacle in the fields of stem cell biology and regenerative medicine.
Stanford scientists have successfully developed the first method for isolating normal, homogeneous, expandable and multipotent neural stem-progenitor cells (NSPCs) from human embryonic stem cells (hESCs), using a defined in vitro method of selection and perpetuation based on t